Back to results
US 2023/0416348 A1Published application
Calreticulin nanobodies
AssigneeActinium Pharmaceuticals, Inc.
InventorsGHOLAMREZA HASSANZADEH GHASSABEH, STEVE SCHOONOOGHE, HELEN KOTANIDES
Life of this patent
Estimating the term…
Abstract
Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.
Claims16
A protein comprising a human-calreticulin binding nanobody amino acid sequence comprising the CDR1, CDR2, and CDR3 amino acid sequences of any one of the nanobody amino acid sequences set forth in SEQ ID NOS:72-134.
Dependencies are inferred from the claim text.